The company blasts the US regulator as weeks of uncertainty for its lead drug in Nash end in a complete response letter.
Biogen’s aducanumab filing is keenly awaited, as are clinical data from Sanofi, Bristol Myers Squibb, Lilly and others.
Five reasons why Astra should buy Gilead, and five why a move of this sort is pure fantasy.
The antiviral is just about positive in a moderate Covid-19 study, but paradoxically only as a limited regimen.
Arcus insists that its new partnership is a good deal, but shareholders make their feelings known.
Filgotinib’s mixed efficacy in ulcerative colitis prompts a shares slide.
Johnson & Johnson is easily the largest big pharma employer, and on certain metrics outstrips smaller rivals.
Clinical data are expected soon from Novo Nordisk, Bayer and Sanofi, while Roche and Gilead take aim at ulcerative colitis.
Gilead’s dominance of the HIV prevention market is set to be challenged by monotherapy.